Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
21 hedge funds and large institutions have $4.31M invested in Statera Biopharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5% less funds holding
Funds holding: 22 → 21 (-1)
23% less capital invested
Capital invested by funds: $5.61M → $4.31M (-$1.3M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$159K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$129K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$101K |
| 4 |
BlackRock
New York
|
+$98.3K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$68.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.13M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$425K |
| 3 |
AIP
ARS Investment Partners
New York
|
-$194K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$192K |
| 5 |
Renaissance Technologies
New York
|
-$175K |
STAB Hedge Fund Activity: Q2 2021 in Review
21 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2021, worth a combined $4.31M — down 23% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of STAB and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $159K. The largest seller was Morgan Stanley, cutting an estimated $1.13M.
- 21 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2021, down from 22 in Q1 2021.
- Funds reported $4.31M of Statera Biopharma, Inc. Common Stock stock for Q2 2021, down 23% quarter-over-quarter.
- 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2021 and 4 closed out, a net change of -1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $159K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2021 was Morgan Stanley, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2021.